Skip to main content
. Author manuscript; available in PMC: 2009 Dec 14.
Published in final edited form as: Stroke. 2007 Dec 6;39(1):220–226. doi: 10.1161/STROKEAHA.107.490946

Figure 1.

Figure 1

Atorvastatin (Ator.) increases NPC proliferation and PS1 and NICD expression after stroke. BrdU, PS1, and NICD expression was measured in the ipsilateral SVZ 28 days after MCAo or sham intervention. A, D, and G show BrdU (A, arrow), PS1 (D, arrow), and NICD (G, arrow) expression, respectively, in the ipsilateral SVZ in MCAo control rats. B, E, and H show BrdU (B, arrow), PS1 (E, arrow), and NICD (H, arrow) expression, respectively, in the ipsilateral SVZ in atorvastatin-treated poststroke rats. G and H inserts are high-magnification views of NICD-positive cells (red); blue color is DAPI nuclear counterstaining. C and I show quantitative data of BrdU- (C) and NICD- (I) positive cell numbers in the ipsilateral SVZ in MCAo or sham-operated control rats treated with or without atorvastatin. F shows quantitative data of the PS1-positive (F) percentage area in the ipsilateral SVZ in MCAo or sham-operated control rats treated with or without atorvastatin. Double immunostaining of PS1 with NICD (J–L) shows colocalization of PS1 (J and L; arrow, cytoplasm) with NICD (K and L; arrow, nucleus). Bar in B and E=50µm